Janux Therapeutics, Inc. (JANX)
Nasdaq: JANX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Feb 26, 2026 | Feb 27, 2025 | Mar 8, 2024 | Mar 10, 2023 | Mar 18, 2022 | · |
| Revenue | 10,000 | 10,588 | 8,083 | 8,612 | 3,637 | 0 |
| Research and development | 125,896 | 68,388 | 54,922 | 53,441 | 26,237 | 3,041 |
| General and administrative | 41,771 | 41,047 | 26,140 | 22,262 | 10,329 | 1,802 |
| Total costs and expenses | 167,667 | 109,435 | 81,062 | 75,703 | 36,566 | 4,843 |
| Operating income | -157,667 | -98,847 | -72,979 | -67,091 | -32,929 | -4,843 |
| Total non-operating income (expense) | 44,042 | 29,853 | 14,686 | 4,032 | 257 | -1,941 |
| Income tax expense | 0 | 0 | 0 | · | · | · |
| Net income including non-controlling interests | -113,625 | -68,994 | -58,293 | -63,059 | -32,672 | -6,784 |
| Net income | -113,625 | -68,994 | -58,293 | -63,059 | -32,672 | -6,784 |
| Earnings per share, basic | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 | · |
| Earnings per share, diluted | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 | · |
| Earnings per share, basic and diluted | · | · | · | · | -0.0262b | -0.1398b |
| Weighted average shares, basic | 61,966,999 | 53,751,480 | 44,016,283 | 41,469,631 | 23,530,252r | 12,387,478b |
| Weighted average shares, diluted | 61,966,999 | 53,751,480 | 44,016,283 | 41,469,631 | 23,530,252 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 1,247,103,356b | 48,502,738b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 53-for-1 split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted